Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq
- PMID: 35688146
- PMCID: PMC9380471
- DOI: 10.1016/j.cell.2022.05.013
Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq
Abstract
A central goal of genetics is to define the relationships between genotypes and phenotypes. High-content phenotypic screens such as Perturb-seq (CRISPR-based screens with single-cell RNA-sequencing readouts) enable massively parallel functional genomic mapping but, to date, have been used at limited scales. Here, we perform genome-scale Perturb-seq targeting all expressed genes with CRISPR interference (CRISPRi) across >2.5 million human cells. We use transcriptional phenotypes to predict the function of poorly characterized genes, uncovering new regulators of ribosome biogenesis (including CCDC86, ZNF236, and SPATA5L1), transcription (C7orf26), and mitochondrial respiration (TMEM242). In addition to assigning gene function, single-cell transcriptional phenotypes allow for in-depth dissection of complex cellular phenomena-from RNA processing to differentiation. We leverage this ability to systematically identify genetic drivers and consequences of aneuploidy and to discover an unanticipated layer of stress-specific regulation of the mitochondrial genome. Our information-rich genotype-phenotype map reveals a multidimensional portrait of gene and cellular function.
Keywords: CRISPR; Integrator complex; Perturb-seq; cell biology; chromosomal instability; genetic screens; genotype-phenotype map; mitochondrial genome stress response; single-cell RNA sequencing.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.M.R. consults for Maze Therapeutics and is a consultant for and equity holder in Waypoint Bio. R.A.S. consults for Maze Therapeutics. K.A. is a consultant for Syros Pharmaceuticals, is on the SAB of CAMP4 Therapeutics, and received research funding from Novartis not related to this work. G.L.-Y., N.I., F.O., and D.L. are employees and shareholders of Ultima Genomics. M.J. consults for Maze Therapeutics and Gate Bioscience. T.M.N. consults for Maze Therapeutics. J.S.W. declares outside interest in 5AM Ventures, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics, and Third Rock Ventures. The Regents of the University of California with R.A.S., T.M.N., M.J., and J.S.W. as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq.
Figures







Comment in
-
Genome-scale single-cell CRISPR screens.Nat Rev Genet. 2022 Aug;23(8):459. doi: 10.1038/s41576-022-00517-1. Nat Rev Genet. 2022. PMID: 35760907 No abstract available.
Similar articles
-
Scalable genetic screening for regulatory circuits using compressed Perturb-seq.Nat Biotechnol. 2024 Aug;42(8):1282-1295. doi: 10.1038/s41587-023-01964-9. Epub 2023 Oct 23. Nat Biotechnol. 2024. PMID: 37872410 Free PMC article.
-
A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response.Cell. 2016 Dec 15;167(7):1867-1882.e21. doi: 10.1016/j.cell.2016.11.048. Cell. 2016. PMID: 27984733 Free PMC article.
-
New Method for Genome-Scale Functional Genomic Study in Bacteria with Superior Performance: CRISPR Interference Screen.Methods Mol Biol. 2022;2377:123-141. doi: 10.1007/978-1-0716-1720-5_7. Methods Mol Biol. 2022. PMID: 34709614
-
Pooled Genome-Scale CRISPR Screens in Single Cells.Annu Rev Genet. 2023 Nov 27;57:223-244. doi: 10.1146/annurev-genet-072920-013842. Epub 2023 Aug 10. Annu Rev Genet. 2023. PMID: 37562410 Review.
-
CRISPR screens for functional interrogation of immunity.Nat Rev Immunol. 2023 Jun;23(6):363-380. doi: 10.1038/s41577-022-00802-4. Epub 2022 Dec 8. Nat Rev Immunol. 2023. PMID: 36481809 Review.
Cited by
-
Defining the extent of gene function using ROC curvature.Bioinformatics. 2022 Dec 13;38(24):5390-5397. doi: 10.1093/bioinformatics/btac692. Bioinformatics. 2022. PMID: 36271855 Free PMC article.
-
In vivo single-cell CRISPR uncovers distinct TNF programmes in tumour evolution.Nature. 2024 Aug;632(8024):419-428. doi: 10.1038/s41586-024-07663-y. Epub 2024 Jul 17. Nature. 2024. PMID: 39020166 Free PMC article.
-
Mapping Stress-Responsive Signaling Pathways Induced by Mitochondrial Proteostasis Perturbations.bioRxiv [Preprint]. 2024 Feb 1:2024.01.30.577830. doi: 10.1101/2024.01.30.577830. bioRxiv. 2024. Update in: Mol Biol Cell. 2024 May 1;35(5):ar74. doi: 10.1091/mbc.E24-01-0041. PMID: 38352575 Free PMC article. Updated. Preprint.
-
Multiplexed engineering and precision gene editing in cellular immunotherapy.Front Immunol. 2022 Nov 22;13:1063303. doi: 10.3389/fimmu.2022.1063303. eCollection 2022. Front Immunol. 2022. PMID: 36483551 Free PMC article. Review.
-
A new method to synthesize multiple gRNA libraries and functional mapping of mammalian H3K4me3 regions.Nucleic Acids Res. 2023 May 22;51(9):e50. doi: 10.1093/nar/gkad198. Nucleic Acids Res. 2023. PMID: 36938898 Free PMC article.
References
-
- Adamson B, Norman TM, Jost M, Cho MY, Nuñez JK, Chen Y, Villalta JE, Gilbert LA, Horlbeck MA, Hein MY, et al. (2016). A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867–1882.e21. 10.1016/j.cell.2016.11.048. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials